Astra, Macleods Settle Patent Suit on Brilinta Blood Thinner

AstraZeneca had claimed that Macleods’s proposed generic version of a blood thinner infringes a patent for AstraZeneca’s Brilinta drug.

• Macleods is blocked from making or selling copies until the patent has expired “unless otherwise specifically authorized” in the confidential settlement agreement, according to consent judgment approved Monday in federal court in Wilmington, Delaware
• Patent, issued in May 2019, expires in January 2036, according to supplemental filing
• The U.S. Food and Drug Administration on May 28 approved Brilinta’s use in the U.S. to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease ...